News
Alkem Sees 8-11% Growth For Indian Pharmaceutical Industry
When the epidemic subsides, Alkem Laboratories predicts that inflationary pressures and shifting regulatory standards will be the primary concerns to keep an eye on, and that normal business operations would allow the Indian pharmaceutical industry to resume its 8–11%...
News
Switzerland To Get A $518mn Fill-Finish Plant From Lonza
Lonza, a major CDMO, is to invest $518 million in a new, massive fill-finish manufacturing facility in Stein, Switzerland. According to the firm, the facility will use sustainable construction methods to lower carbon emissions when it is finished in...
News
Pfizer And Touchlight Enter Into A Patent Licence Agreement
Pfizer and another pharmaceutical major, Touchlight, have come to a deal on a significant non-exclusive patent licence. Touchlight is a firm that focuses on enzymatic DNA manufacturing to further enhance genetic therapies.
As a result of the licencing arrangement, Pfizer...
News
AstraZeneca, GSK Overcame Q2 Issues While Roche Stocks Fell
The standard response to any poor performance is to blame the supply chain, which has almost attained the status of a joke. However, it is now one of a serious group of interconnected economic headwinds that also includes the...
News
Deloitte Latest Survey – Mature R&D Yields Enterprise Value
According to the third Real-World Evidence (RWE) benchmarking survey published in June 2022 by Deloitte, there is a segmentation of outcomes between businesses with more developed organisational and technological RWE capabilities and those with less developed skills.
Since Deloitte's latest...
News
Sanofi Starts Fund For The Concerned In Low-Income Nations
The Paris-based pharmaceutical company is setting up a fund to assist companies who want to provide healthcare solutions in neglected areas. The objective is to assist in the establishment of locally resilient organisations.
According to Jon Fairest of Sanofi, innovation...
News
Novel Ovarian Cancer Treatment By GSK Approved In Singapore
The oral, once-daily Zejula (niraparib) tablet, a first-line and recurrent upkeep care for women with advanced epithelial high-grade ovarian, fallopian tube, or primary peritoneal cancer who are in full or partial remission after platinum-based chemotherapy, has been approved by...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.